Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Ublituximab-xiiy (Briumvi)

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)FDA safety resources (3)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

BRIUMVI™ -ublituximab-xiiy (opens in a new tab)Original source URL: https://globalrph.com/dilution/briumvi-ublituximab-xiiy/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/briumvi-ublituximab-xiiy/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:46:18.733469+00:00
Source location
div.post-content
Packaged content SHA-256
0ee2cb54f9e76402a29744cd91e19598c1b00bc1048c91877f27287f4b7a552b
Original response SHA-256
de7a1cb4aa90237ec98c82319b0cf4be7edb8b47a645535d1535ff16016c4fda
Source body SHA-256
48ebde1b665ab3ec7169de564185170830785666b97c8012b857d801c99e7057

BRIUMVI™ (ublituximab-xiiy) injection

PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information (pdf)]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

0.9% Sodium Chloride (NS)

Standard Dilutions [Amt of drug] [Infusion vol] [Infusion rate] Return to article top

First infusion:
[ 150 mg] [250 mL ] [4 hours - See below]
  • Start at 10 mL per hour for the first 30 minutes
  • Increase to 20 mL per hour for the next 30 minutes
  • Increase to 35 mL per hour for the next hour
  • IIncrease to 100 mL per hour for the remaining 2 hours

Second and subsequent infusions:
[ 450 mg] [250 mL ] 1 hour - See below]
Withdraw 18 mL 0.9% Sodium Chloride Injection, USP from the 250 mL infusion bag and discard.

  • Start at 100 mL per hour for the first 30 minutes
  • Increase to 400 mL per hour for the remaining 30 minutes

  • Review assessments Prior to First Dose of BRIUMVI in the dosage and administration section below.
  • Review assessment and Premedication Before Every Infusion
  • Use the prepared infusion solution immediately. If the diluted solution is not administered immediately, store refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours. Do not freeze. If the diluted solution is stored refrigerated, allow it to equilibrate to room temperature prior to administration (approximately 2 hours). The diluted solution can be stored for an additional 8 hours at room temperature up to 25°C (77°F), which includes the equilibration time and infusion time.

Description:
Ublituximab-xiiy is a recombinant chimeric monoclonal IgG1 antibody with reduced fucose content directed against CD20-expressing B-cells. The molecular weight of the antibody is approximately 147 kDa.

BRIUMVI (ublituximab-xiiy) injection for intravenous infusion is a sterile, clear to opalescent, colorless to slightly yellow, preservative-free solution. Each mL of solution contains 25 mg ublituximab-xiiy, 0.4 mg hydrochloric acid, 0.7 mg polysorbate 80, 9.0 mg sodium chloride, 6.4 mg sodium citrate, and Water for Injection, USP. The pH is 6.5.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:

The precise mechanism by which ublituximab-xiiy exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ublituximab-xiiy results in cell lysis through mechanisms including antibody-dependent cellular cytolysis and complement-dependent cytolysis.

INDICATIONS AND USAGE Return to article top

INDICATIONS AND USAGE:

BRIUMVI is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

CONTRAINDICATIONS Return to article top

Contraindications:
  • Active hepatitis B virus infection
  • History of life-threatening infusion reaction to BRIUMV
WARNINGS AND PRECAUTIONS:
  • Infusion Reactions: Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue BRIUMVI if a life-threatening or disabling infusion reaction occurs ( 2.3, 5.1). Drug information (pdf)
  • Infections: Serious, including life-threatening and fatal infections, have occurred. Delay BRIUMVI administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with BRIUMVI and after discontinuation, until B-cell repletion ( 5.2).
  • Reduction in Immunoglobulins: Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with BRIUMVI, until B-cell repletion, and especially when recurrent serious infections are suspected. Consider discontinuing BRIUMVI in patients with serious opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins ( 2.1, 5.4).
  • Fetal Risk: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for at least 6 months after stopping BRIUMVI ( 5.3, 8.1, 8.3). Drug information (pdf)

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:
The most common adverse reactions (≥10%) were infusion reactions and upper respiratory tract infections ( 6.1).

See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication Guide. Drug information (pdf)

DOSAGE AND ADMINISTRATION Return to article top

DOSAGE AND ADMINISTRATION:
2.1 Assessments Prior to First Dose of BRIUMVI

Hepatitis B Virus Screening

Prior to initiating BRIUMVI, perform Hepatitis B virus (HBV) screening. BRIUMVI is contraindicated in patients with active HBV confirmed by positive results for Hepatitis B surface antigen [HBsAg] and anti-HBV tests. For patients who are negative for HBsAg and positive for Hepatitis B core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment with BRIUMVI [see Warnings and Precautions ( 5.2)] .

Serum Immunoglobulins

Prior to initiating BRIUMVI, perform testing for quantitative serum immunoglobulins [see Warnings and Precautions ( 5.4)]. For patients with low serum immunoglobulins, consult immunology experts before initiating treatment with BRIUMVI.

Vaccinations

Because vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation until B-cell repletion, administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of BRIUMVI for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines [see Warnings and Precautions ( 5.2) and Clinical Pharmacology ( 12.2)] . Drug information (pdf)

2.2 Assessment and Premedication Before Every Infusion

Infection Assessment

Prior to every infusion of BRIUMVI, determine whether there is an active infection. In case of active infection, delay infusion of BRIUMVI until the infection resolves [see Warnings and Precautions ( 5.2)] .

Recommended Premedication

Pre-medicate with 100 mg of methylprednisolone administered intravenously (or an equivalent oral dosage or equivalent corticosteroid) approximately 30 minutes prior to each BRIUMVI infusion to reduce the frequency and severity of infusion reactions [see Warnings and Precautions ( 5.1)] . Pre-medicate with an antihistamine (e.g., diphenhydramine) administered orally or intravenously approximately 30-60 minutes prior to each BRIUMVI infusion to further reduce the frequency and severity of infusion reactions.

The addition of an antipyretic (e.g., acetaminophen) may also be considered.

Pregnancy Testing

Pregnancy testing is recommended for females of reproductive potential prior to each infusion with BRIUMVI [see Warnings and Precautions ( 5.3) and Use in Specific Populations ( 8.1, 8.3)]. Drug information (pdf)

2.3 Recommended Dosage and Dose Administration

Administer BRIUMVI under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions, such as serious infusion reactions.

  • First Infusion: 150 mg intravenous infusion
  • Second Infusion: 450 mg intravenous infusion administered two weeks after the first infusion
  • Subsequent Infusions: 450 mg intravenous infusion administered 24 weeks after the first infusion and every 24 weeks thereafter
  • Observe the patient for at least one hour after the completion of the first two infusions. Post-infusion monitoring of subsequent infusions is at physician discretion unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion [see Warnings and Precautions ( 5.1)].
Table 1: Recommended Dose, Infusion Rate, and Infusion Duration for MS
Dose (mg) and Volume (mL) of BRIUMVI Volume (mL) of 0.9% Sodium Chloride Injection, USP1 Infusion Rate (mL/hour) Duration2
First Infusion 150 mg
(6 mL)		 250 mL
  • Start at 10 mL per hour for the first 30 minutes
  • Increase to 20 mL per hour for the next 30 minutes
  • Increase to 35 mL per hour for the next hour
  • Increase to 100 mL per hour for the remaining 2 hours
 4 hours
Second Infusion
(2 weeks later)		 450 mg
(18 mL)		 250 mL
  • Start at 100 mL per hour for the first 30 minutes
  • Increase to 400 mL per hour for the remaining 30 minutes
 1 hour
Subsequent Infusions
(once every 24 weeks) 3		 450 mg
(18 mL)		 250 mL
  • Start at 100 mL per hour for the first 30 minutes
  • Increase to 400 mL per hour for the remaining 30 minutes
 1 hour

1. Withdraw and discard the required volume of 0.9% Sodium Chloride Injection, USP from the infusion bag following the preparation instructions in Preparation and Administration ( 2.6).

2. Infusion duration may take longer if the infusion is interrupted or slowed.

3. Administer the first subsequent infusion 24 weeks after the first infusion.

2.4 Delayed or Missed Doses

If a planned infusion of BRIUMVI is missed, administer BRIUMVI as soon as possible; do not wait until the next scheduled infusion. Reset the infusion schedule to administer the next sequential infusion 24 weeks after the missed infusion is administered. Infusions of BRIUMVI must be separated by at least 5 months.

2.5 Dosage Modifications Because of Infusion Reactions

Dose modifications in response to infusion reactions depend on the severity.

Life-Threatening Infusion Reactions

Immediately stop infusion and permanently discontinue BRIUMVI if there are signs of a life-threatening or disabling infusion reaction [see Warnings and Precautions ( 5.1)] . Provide appropriate supportive treatment.

Severe Infusion Reactions

Immediately interrupt the infusion and administer appropriate supportive treatment, as necessary [see Warnings and Precautions ( 5.1)] . Restart the infusion only after all symptoms have resolved. When restarting, begin at half of the infusion rate at the time of onset of the infusion reaction [see Dosage and Administration ( 2.3)] . If this rate is tolerated, increase the rate as described in TABLE 1. This change in rate will increase the total duration of the infusion but not the total dose.

Mild to Moderate Infusion Reactions

Reduce the infusion rate to half the rate at the onset of the infusion reaction and maintain the reduced rate for at least 30 minutes [see Warnings and Precautions ( 5.1)] . If the reduced rate is tolerated, increase the rate as described in TABLE 1. This change in rate will increase the total duration of the infusion but not the total dose.

2.6 Preparation and Administration

Preparation

Only use 0.9% Sodium Chloride Injection, USP to dilute BRIUMVI.

BRIUMVI must be prepared by a healthcare professional using aseptic technique. Prepare the solution for infusion as follows:

  • BRIUMVI should be a clear to opalescent, colorless to slightly yellow solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use the solution if discolored or if the solution contains discrete foreign particulate matter.

Preparation of Solution for First Infusion:

  • Prepare infusion bag for First Infusion (150 mg) using one vial (150 mg/6 mL) of BRIUMVI.
  • Withdraw 6 mL 0.9% Sodium Chloride Injection, USP from the 250 mL infusion bag and discard.
  • Withdraw 6 mL BRIUMVI solution from the vial.
  • Add 6 mL (150 mg) BRIUMVI into the infusion bag containing 0.9% Sodium Chloride Injection, USP.

Preparation of Solution for Second Infusion and Subsequent Infusions:

  • Prepare infusion bag for Second Infusion (450 mg) and Subsequent Infusions (450 mg) using three vials (150 mg/6 mL) of BRIUMVI.
  • Withdraw 18 mL 0.9% Sodium Chloride Injection, USP from the 250 mL infusion bag and discard.
  • Withdraw 18 mL BRIUMVI solution from the vials (6 mL/vial).
  • Add 18 mL (450 mg) BRIUMVI into the infusion bag containing 0.9% Sodium Chloride Injection, USP.

Mix diluted solution by gentle inversion. Do not shake.

Administration of Infusion Solution

Prior to the start of the intravenous infusion, the contents of the infusion bag should be at room temperature [see Dosage and Administration ( 2.7)] .

Administer the diluted infusion solution through a dedicated line.

No incompatibilities between BRIUMVI and polyvinyl chloride (PVC) or polyolefin (PO) bags and intravenous (IV) administration sets have been observed.

2.7 Storage Instructions for the Prepared Infusion Solution

Use the prepared infusion solution immediately. If the diluted solution is not administered immediately, store refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours. Do not freeze. If the diluted solution is stored refrigerated, allow it to equilibrate to room temperature prior to administration (approximately 2 hours). The diluted solution can be stored for an additional 8 hours at room temperature up to 25°C (77°F), which includes the equilibration time and infusion time.

DOSAGE FORMS AND STRENGTHS:
Injection: 150 mg/6 mL (25 mg/mL) in a single-dose vial

Storage and Stability Return to article top

Storage and Handling

Store BRIUMVI vials refrigerated at 2°C to 8°C (36°F to 46°F) in the outer carton to protect from light. Do not freeze. Do not shake.

Diluted solution:
Use the prepared infusion solution immediately. If the diluted solution is not administered immediately, store refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours. Do not freeze. If the diluted solution is stored refrigerated, allow it to equilibrate to room temperature prior to administration (approximately 2 hours). The diluted solution can be stored for an additional 8 hours at room temperature up to 25°C (77°F), which includes the equilibration time and infusion time.

Open this historical article on its own

FDA safety resources for this medication (3)
  • FDA AEMS Q1 2026: Pneumocystis jirovecii infection - no action needed at that time (status 2026-06-04) (opens in a new tab)
    Dated FDA status and source scope

    Potential-signal tables are safety-review resources. Inclusion alone does not establish causality or a treatment change.

    FDA table status date: 2026-06-04

    Status in that table: FDA determined that no action was needed at the time based on available information.

    Exact table location: January - March 2026 safety table, data row 5 (header excluded): Product Name / Product Class = Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Ocrevus (ocrelizumab) injection Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) injection; Signal = Pneumocystis jirovecii infection; Additional Information (as of 2026-06-04)

    Scope: Matches the expressly listed product/ingredient for safety-resource navigation only. It does not reconcile a stocked manufacturer, package NDC, lot or full monograph and does not establish causality.

    Interpretation: No action needed at that time is not a declaration that the product cannot cause the event, that all infection risk is absent, or that existing labeling precautions should be removed.

  • FDA AEMS Q2 2026: Pneumonitis - evaluating regulatory action (status 2026-09-04) (opens in a new tab)
    Dated FDA status and source scope

    Potential-signal tables are safety-review resources. Inclusion alone does not establish causality or a treatment change.

    FDA table status date: 2026-09-04

    Status in that table: FDA is evaluating the need for regulatory action.

    Exact table location: April - June 2026 safety table, data row 3 (header excluded): Product Name / Product Class = Anti-CD20 monoclonal antibodies Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Ocrevus (ocrelizumab) injection Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) injection; Signal = Pneumonitis; Additional Information (as of 2026-09-04)

    Scope: Matches the expressly listed product/ingredient for safety-resource navigation only. It does not reconcile a stocked manufacturer, package NDC, lot or full monograph and does not establish causality.

  • FDA AEMS Q2 2026: Serum sickness - evaluating regulatory action (status 2026-09-04) (opens in a new tab)
    Dated FDA status and source scope

    Potential-signal tables are safety-review resources. Inclusion alone does not establish causality or a treatment change.

    FDA table status date: 2026-09-04

    Status in that table: FDA is evaluating the need for regulatory action.

    Exact table location: April - June 2026 safety table, data row 4 (header excluded): Product Name / Product Class = Anti-CD20 monoclonal antibodies Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Ocrevus (ocrelizumab) injection Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) injection; Signal = Serum sickness; Additional Information (as of 2026-09-04)

    Scope: Matches the expressly listed product/ingredient for safety-resource navigation only. It does not reconcile a stocked manufacturer, package NDC, lot or full monograph and does not establish causality.

Read the linked communication and current prescribing information before use. Resource dates and affected product scopes differ; a listed resource is not a full monograph or a lot-specific clearance.

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ublituximab-xiiy-briumvi
      Source IDH51-55B0A3DF4921C9ED0501AECB
      Generic name
      Ublituximab-xiiy (Briumvi)
      Source IDH51-DF0EE18D6ACCC46031873368
      Class
      Biologics and immunotherapy
      Source IDH51-C8A52DCF23B1A53CA20D6687
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-C8D09EBEB55BE404ED0A801E
      Primary uses
      1. The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic.
        Source IDH51-25370C79EEEB7E5EB49531E5
      Mechanism
      Binds CD20 on B lymphocytes and produces immune-mediated B-cell depletion.
      Source IDH51-E5052F1FA8069E351A232361
      Mechanism level
      drug_specific
      Source IDH51-F06107E6F88746011950A145
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-2C22561EA5DC2DB2C0DBEF93
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-C2A16CC4143FD7B7C86754E4
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-E1E2F5A4D90045F0808B3580
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-17C0BB058ACC8B9AE31A820F
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-A25D3F9B176F41A545BB4D4E
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-ACEC045EAF88C3DE8399B9B3
      Legacy title
      Ublituximab-xiiy (Briumvi)
      Source IDH51-07366084C9CBCE3DFBB5F331
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-72ABE48E726D32BD0B2E3BCA
      Search text
      Ublituximab-xiiy (Briumvi) Biologics and immunotherapy Legacy GlobalRPh directory entry The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic. Binds CD20 on B lymphocytes and produces immune-mediated B-cell depletion. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-13B89414A323AD71B4A138B6
      Official access mode
      none
      Source IDH51-3FD8A04DD43A42CAC28951ED
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-52B527FF236DF351806C20FB

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-4F0926B1F7F3D0CA3A9AFF78
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-AD0E44B28291A5B681AB0536
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-9941766AE2BA2B1919F48848

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-0E195BADAC33E1E1D0D2FC46

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-946550B3C70E02092F8E0E20
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      ublituximab-xiiy-briumvi
      Source IDH51-5F9FEFEBAD5A5925103FBB33
      Legacy title
      Ublituximab-xiiy (Briumvi)
      Source IDH51-E45E5DF6807E1EA9D426A2A8
      Generic name
      Ublituximab-xiiy (Briumvi)
      Source IDH51-66BC408A0EF437F5F000C487
      Class
      Biologics and immunotherapy
      Source IDH51-D0100C9820F8ADF70EA6D7B5
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-4B5DAB5A0FFEC2CE31A88D25
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-A2A4BE03D36CB0C00586512F
      Populations
      1. Population not yet normalized
        Source IDH51-51E190892F23D69C86E4ED6C
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-5F4998C09F2BC9B98709B5CA
      High alert
      false
      Source IDH51-46EB50BB2533D0E3B2DE5DD7
      Hazardous
      false
      Source IDH51-E51CAA747D1BF7FBB7631638
      Status
      Legacy migration
      Source IDH51-B9C19FD2CB1A0549D7D1ECEC
      Version added
      Legacy
      Source IDH51-53ED4BA933BF4CF18ABBD3C5
      Sources
      LabelUrlKind
      Source IDH51-40A1ECDD5EFB1B9E81479A92
      GlobalRPh legacy IV dilution monograph
      Source IDH51-462F59616E9432377A1D63A1
      		legacy:auto
      Source IDH51-A67A44D7D10E591227C202F4
      		Legacy
      Source IDH51-0C539666C15713BD54C21430
      Clinical release verification
      Audit version
      3.4
      Source IDH51-C3D7B3A8551959BFDE4B4970
      Audited on
      2026-08-30
      Source IDH51-258EB002B94B479BF08B70C4
      Level
      red
      Source IDH51-2843DD0DCC0BCB012E5685DE
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-08CEEC5DAB4F824B872E5A6B
      Exact current label candidate
      false
      Source IDH51-98127A485BDC463E9201EFB8
      Reference url count
      0
      Source IDH51-B658AD0B06A6DA9E8F7E66C6
      Broken reference count
      0
      Source IDH51-8730A229E19D30DF90FE3129
      Point of use confirmation required
      true
      Source IDH51-929ECBC6F8ADA91BA4FE08C8
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-0A18D67E1E9630281F9ABD87

      Dosing source fields

      Id
      ublituximab-xiiy-briumvi
      Source IDH51-E78A6915CE8AB0F9FEB21B42
      Generic name
      Ublituximab-xiiy (Briumvi)
      Source IDH51-5D7B5E4EB09B219B366EE785
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-65B875D300BB484E57FD2015
      Package insert
      Query name
      Ublituximab-xiiy
      Source IDH51-B97ACB5CB1B97994F5096C33
      Product and route must match
      true
      Source IDH51-C0FFA05E1A1EBA59536E993A
      Live current label enabled
      false
      Source IDH51-89FCD0F70EEEF8D64060B0C7
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-38E555CF034F1D98DC314D31
      Direct official label access enabled
      true
      Source IDH51-09E1FA47F72E8E66D7E18FB3
      Outbound server request required
      false
      Source IDH51-CE8127350A41ABFD0EA819B1
      Local summary status
      not_bundled
      Source IDH51-E6ADEE3A41AC4C80907E61C4
      Clinical review
      Locally normalized
      false
      Source IDH51-5B2ACD2987890E3C23D30027
      Reviewed
      2026-08-29
      Source IDH51-3457EFCB161AD16DEF60A11E
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-C8B7AE35FFE312317A1710F7
      Clinical release verification
      Audit version
      3.4
      Source IDH51-93765549AFD2901D05BA0085
      Audited on
      2026-08-30
      Source IDH51-061FDB36B749A321125F535D
      Level
      red
      Source IDH51-303B161254A9630CC4207033
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-451D678CC7FE2C17C9262EC4
      Exact current label candidate
      false
      Source IDH51-33BE307BB587BEAF737947EE
      Reference url count
      0
      Source IDH51-A6196EBFDD649664A0F58A2C
      Broken reference count
      0
      Source IDH51-6DEDC247C1BD525C06B8658D
      Point of use confirmation required
      true
      Source IDH51-02277EE5DBACBC0C9F15B5E9
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-907DDDA3FABE52590AAC0839
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ublituximab-xiiy-briumvi
      Source IDH51-505DD41E6941A5E90F4A0E96
      Name
      Ublituximab-xiiy (Briumvi)
      Source IDH51-5489E700FA0B05169DCBFFB5
      Therapeutic class
      Biologics and immunotherapy
      Source IDH51-1086A09DED8777C9E97E29CC
      Review version
      3.1
      Source IDH51-0583784F0E5E40E12BF93819
      Review date
      2026-08-30
      Source IDH51-AFB2A7D7BD3D06F1C04DCDF2
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-87C8251D7E2643278403CF23
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-612C8D0C1DACB6EDB6D27EA0
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-0F0E582D4F0626E6E65516DC
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-1C215FDCF648C72B359CAC41
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-1B3EF012762C7D6DE79AB5F9
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-8EF7F9D3E78C57E490594070
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-39FD55925A5506E96528944C
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-A64D14B99FD2D0A10462D49E
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-6F2CF5B82FD4CBFA325FB76C
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-4D90CB637B53422295E7AA0B
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-B54FF386331F080108A8FB15
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-834A734B66211DEEC6F766A0
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-603CE6D67E6F2B9F4B068074
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-4F12B2E39129DD8236CC551A
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-96A2742D96D8C3D89699F9E8
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-AACE6F8B0984DBE3CD2838EB
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-858A03172D9DEC2637978ED2
      Adult dosing range
      Primary
      not_found
      Source IDH51-843DB41D433F91F969258CC9
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-1118F3785EB598FDCE0ED58A
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-2E01F57CA44BEA2157F3FB65
      Infusion time
      Primary
      not_found
      Source IDH51-4B200B47ACED58C77DD0CE53
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-168FF81F3F96CE1586C4A45E
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-6A5D01DEAF88DC5F0B5B0E26
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-08B27B1C844ABE3E8D6C594F
      Guide generation allowed
      false
      Source IDH51-254277CC8FEB9705EDB7B5A6
      Pediatric
      Applicability
      not_established
      Source IDH51-E83001BE517046AF34FAFF5A
      Guide generation allowed
      false
      Source IDH51-27D154503A5F0B97B87E7BCF
      Neonatal
      Applicability
      not_established
      Source IDH51-776CEAC441492113C76C485F
      Guide generation allowed
      false
      Source IDH51-533FF13D2C7D7721A58B0330
      Route presence
      Structured dilution
      false
      Source IDH51-A46CF76D3587DE4FA0BFA51F
      Iv push
      false
      Source IDH51-3DBF5C8B73DA290A07FE657C
      Continuous infusion
      false
      Source IDH51-2B7C87E494EDC515FC6275A4
      Pediatric source
      false
      Source IDH51-1FF14AEDF091B82F96A9EAAC
      Neonatal source
      false
      Source IDH51-55E65C86FDD21C662D9EBA05
      Legacy reference
      Status
      not_available
      Source IDH51-60A380301544E90385909CF9
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-3F5480B3E3EF56AB37D45EB8
      Source files
      1. catalog.json
        Source IDH51-1A79743810A0262D58DE4EC2
      2. dosing.json
        Source IDH51-B23B4904668011E95E811FE3
      3. legacy-map.json
        Source IDH51-A4E357960B9FA0FFDFDA9855
      4. review-queue.json
        Source IDH51-1A4215D78D10BFF9D65F9CD6
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-6F441167E48ABAD217FF1BF8
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-5F9FEFEBAD5A5925103FBB33catalog.json
      /records/245/id      		Historical; current review incomplete
      H51-E45E5DF6807E1EA9D426A2A8catalog.json
      /records/245/legacy_title      		Historical; current review incomplete
      H51-66BC408A0EF437F5F000C487catalog.json
      /records/245/generic_name      		Historical; current review incomplete
      H51-D0100C9820F8ADF70EA6D7B5catalog.json
      /records/245/class      		Historical; current review incomplete
      H51-4B5DAB5A0FFEC2CE31A88D25catalog.json
      /records/245/subclass      		Historical; current review incomplete
      H51-A2A4BE03D36CB0C00586512Fcatalog.json
      /records/245/summary      		Historical; current review incomplete
      H51-0E195BADAC33E1E1D0D2FC46catalog.json
      /records/245/warnings/0      		Historical; current review incomplete
      H51-946550B3C70E02092F8E0E20catalog.json
      /records/245/stability_notes/0      		Historical; current review incomplete
      H51-51E190892F23D69C86E4ED6Ccatalog.json
      /records/245/populations/0      		Historical; current review incomplete
      H51-5F4998C09F2BC9B98709B5CAcatalog.json
      /records/245/evidence_tier      		Historical; current review incomplete
      H51-46EB50BB2533D0E3B2DE5DD7catalog.json
      /records/245/high_alert      		Historical; current review incomplete
      H51-E51CAA747D1BF7FBB7631638catalog.json
      /records/245/hazardous      		Historical; current review incomplete
      H51-B9C19FD2CB1A0549D7D1ECECcatalog.json
      /records/245/status      		Historical; current review incomplete
      H51-0C3C5713A448D4EC54F7FBB4catalog.json
      /records/245/reviewed      		Historical; current review incomplete
      H51-53ED4BA933BF4CF18ABBD3C5catalog.json
      /records/245/version_added      		Historical; current review incomplete
      H51-40A1ECDD5EFB1B9E81479A92catalog.json
      /records/245/sources/0      		Historical; current review incomplete
      H51-462F59616E9432377A1D63A1catalog.json
      /records/245/sources/0/label      		Historical; current review incomplete
      H51-A67A44D7D10E591227C202F4catalog.json
      /records/245/sources/0/url      		Historical; current review incomplete
      H51-0C539666C15713BD54C21430catalog.json
      /records/245/sources/0/kind      		Historical; current review incomplete
      H51-C3D7B3A8551959BFDE4B4970catalog.json
      /records/245/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-258EB002B94B479BF08B70C4catalog.json
      /records/245/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-2843DD0DCC0BCB012E5685DEcatalog.json
      /records/245/clinical_release_verification/level      		Historical; current review incomplete
      H51-08CEEC5DAB4F824B872E5A6Bcatalog.json
      /records/245/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-98127A485BDC463E9201EFB8catalog.json
      /records/245/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-F1075D06D93BD6218A4D12A9catalog.json
      /records/245/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-78D51830956EAAFD576BEDC0catalog.json
      /records/245/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-CD92531426A4336A69F2149Ccatalog.json
      /records/245/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-B658AD0B06A6DA9E8F7E66C6catalog.json
      /records/245/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-8730A229E19D30DF90FE3129catalog.json
      /records/245/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-929ECBC6F8ADA91BA4FE08C8catalog.json
      /records/245/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-0A18D67E1E9630281F9ABD87catalog.json
      /records/245/clinical_release_verification/note      		Historical; current review incomplete
      H51-BF1A1514C21140FFF6CE94C0catalog.json
      /records/245/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-E78A6915CE8AB0F9FEB21B42dosing.json
      /records/245/id      		Historical; current review incomplete
      H51-5D7B5E4EB09B219B366EE785dosing.json
      /records/245/generic_name      		Historical; current review incomplete
      H51-65B875D300BB484E57FD2015dosing.json
      /records/245/coverage_status      		Historical; current review incomplete
      H51-B97ACB5CB1B97994F5096C33dosing.json
      /records/245/package_insert/query_name      		Historical; current review incomplete
      H51-E02CC44C84A6037DC842E6BBdosing.json
      /records/245/package_insert/preferred_setid      		Historical; current review incomplete
      H51-C0FFA05E1A1EBA59536E993Adosing.json
      /records/245/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-89FCD0F70EEEF8D64060B0C7dosing.json
      /records/245/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-38E555CF034F1D98DC314D31dosing.json
      /records/245/package_insert/source_priority      		Historical; current review incomplete
      H51-09E1FA47F72E8E66D7E18FB3dosing.json
      /records/245/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-CE8127350A41ABFD0EA819B1dosing.json
      /records/245/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-E6ADEE3A41AC4C80907E61C4dosing.json
      /records/245/package_insert/local_summary_status      		Historical; current review incomplete
      H51-4F0926B1F7F3D0CA3A9AFF78dosing.json
      /records/245/renal/classification      		Historical; current review incomplete
      H51-AD0E44B28291A5B681AB0536dosing.json
      /records/245/renal/summary      		Historical; current review incomplete
      H51-9941766AE2BA2B1919F48848dosing.json
      /records/245/renal/method_note      		Historical; current review incomplete
      H51-5B2ACD2987890E3C23D30027dosing.json
      /records/245/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-3457EFCB161AD16DEF60A11Edosing.json
      /records/245/clinical_review/reviewed      		Historical; current review incomplete
      H51-C8B7AE35FFE312317A1710F7dosing.json
      /records/245/clinical_review/status      		Historical; current review incomplete
      H51-93765549AFD2901D05BA0085dosing.json
      /records/245/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-061FDB36B749A321125F535Ddosing.json
      /records/245/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-303B161254A9630CC4207033dosing.json
      /records/245/clinical_release_verification/level      		Historical; current review incomplete
      H51-451D678CC7FE2C17C9262EC4dosing.json
      /records/245/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-33BE307BB587BEAF737947EEdosing.json
      /records/245/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-9CF43E6FBAB6A9572481D49Bdosing.json
      /records/245/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-C681F45AFB6E46430B942447dosing.json
      /records/245/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-A8F9D1BFDEC66727FEA31627dosing.json
      /records/245/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-A6196EBFDD649664A0F58A2Cdosing.json
      /records/245/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-6DEDC247C1BD525C06B8658Ddosing.json
      /records/245/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-02277EE5DBACBC0C9F15B5E9dosing.json
      /records/245/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-907DDDA3FABE52590AAC0839dosing.json
      /records/245/clinical_release_verification/note      		Historical; current review incomplete
      H51-3D7BBF61ABA9BE196DEED5E2dosing.json
      /records/245/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-55B0A3DF4921C9ED0501AECBfirst-look-v5.1.json
      /records/245/id      		Historical; current review incomplete
      H51-DF0EE18D6ACCC46031873368first-look-v5.1.json
      /records/245/generic_name      		Historical; current review incomplete
      H51-C8A52DCF23B1A53CA20D6687first-look-v5.1.json
      /records/245/class      		Historical; current review incomplete
      H51-C8D09EBEB55BE404ED0A801Efirst-look-v5.1.json
      /records/245/subclass      		Historical; current review incomplete
      H51-25370C79EEEB7E5EB49531E5first-look-v5.1.json
      /records/245/primary_uses/0      		Historical; current review incomplete
      H51-E5052F1FA8069E351A232361first-look-v5.1.json
      /records/245/mechanism      		Historical; current review incomplete
      H51-F06107E6F88746011950A145first-look-v5.1.json
      /records/245/mechanism_level      		Historical; current review incomplete
      H51-2C22561EA5DC2DB2C0DBEF93first-look-v5.1.json
      /records/245/basic_dosing_orientation      		Historical; current review incomplete
      H51-C2A16CC4143FD7B7C86754E4first-look-v5.1.json
      /records/245/administration_orientation      		Historical; current review incomplete
      H51-E1E2F5A4D90045F0808B3580first-look-v5.1.json
      /records/245/renal_and_population_orientation      		Historical; current review incomplete
      H51-17C0BB058ACC8B9AE31A820Ffirst-look-v5.1.json
      /records/245/key_safety_orientation/0      		Historical; current review incomplete
      H51-A25D3F9B176F41A545BB4D4Efirst-look-v5.1.json
      /records/245/coverage_path      		Historical; current review incomplete
      H51-ACEC045EAF88C3DE8399B9B3first-look-v5.1.json
      /records/245/coverage_path_label      		Historical; current review incomplete
      H51-B8B86AC194EDFE55F428063Afirst-look-v5.1.json
      /records/245/official_label_url      		Historical; current review incomplete
      H51-07366084C9CBCE3DFBB5F331first-look-v5.1.json
      /records/245/legacy_title      		Historical; current review incomplete
      H51-72ABE48E726D32BD0B2E3BCAfirst-look-v5.1.json
      /records/245/review_note      		Historical; current review incomplete
      H51-13B89414A323AD71B4A138B6first-look-v5.1.json
      /records/245/search_text      		Historical; current review incomplete
      H51-D447C0234E60156CDDED3123first-look-v5.1.json
      /records/245/official_search_url      		Historical; current review incomplete
      H51-3FD8A04DD43A42CAC28951EDfirst-look-v5.1.json
      /records/245/official_access_mode      		Historical; current review incomplete
      H51-E8F50A775AB3AA03BBC84AB4first-look-v5.1.json
      /records/245/official_access_url      		Historical; current review incomplete
      H51-E4D9C8E7B9F9F5898D67780Ffirst-look-v5.1.json
      /records/245/official_search_query      		Historical; current review incomplete
      H51-52B527FF236DF351806C20FBfirst-look-v5.1.json
      /records/245/official_access_reason      		Historical; current review incomplete
      H51-505DD41E6941A5E90F4A0E96preparation-assessments-v3.8.json
      /245/id      		Historical; current review incomplete
      H51-5489E700FA0B05169DCBFFB5preparation-assessments-v3.8.json
      /245/name      		Historical; current review incomplete
      H51-8894BA84C59CBA059107921Apreparation-assessments-v3.8.json
      /245/brands      		Historical; current review incomplete
      H51-1086A09DED8777C9E97E29CCpreparation-assessments-v3.8.json
      /245/therapeutic_class      		Historical; current review incomplete
      H51-0583784F0E5E40E12BF93819preparation-assessments-v3.8.json
      /245/review_version      		Historical; current review incomplete
      H51-AFB2A7D7BD3D06F1C04DCDF2preparation-assessments-v3.8.json
      /245/review_date      		Historical; current review incomplete
      H51-87C8251D7E2643278403CF23preparation-assessments-v3.8.json
      /245/release_status      		Historical; current review incomplete
      H51-612C8D0C1DACB6EDB6D27EA0preparation-assessments-v3.8.json
      /245/market_status/status      		Historical; current review incomplete
      H51-0F0E582D4F0626E6E65516DCpreparation-assessments-v3.8.json
      /245/market_status/basis      		Historical; current review incomplete
      H51-1C215FDCF648C72B359CAC41preparation-assessments-v3.8.json
      /245/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-1B3EF012762C7D6DE79AB5F9preparation-assessments-v3.8.json
      /245/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-8EF7F9D3E78C57E490594070preparation-assessments-v3.8.json
      /245/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-39FD55925A5506E96528944Cpreparation-assessments-v3.8.json
      /245/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-A64D14B99FD2D0A10462D49Epreparation-assessments-v3.8.json
      /245/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-6F2CF5B82FD4CBFA325FB76Cpreparation-assessments-v3.8.json
      /245/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-4D90CB637B53422295E7AA0Bpreparation-assessments-v3.8.json
      /245/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-B54FF386331F080108A8FB15preparation-assessments-v3.8.json
      /245/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-834A734B66211DEEC6F766A0preparation-assessments-v3.8.json
      /245/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-A7A534ACD67DB9CB6F7A7AEBpreparation-assessments-v3.8.json
      /245/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-816C31FFACB3532B46F34FF0preparation-assessments-v3.8.json
      /245/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-B3C09765A934D2D4B6CEA62Cpreparation-assessments-v3.8.json
      /245/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-8C0E89EA0045783D0E8ECA60preparation-assessments-v3.8.json
      /245/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-603CE6D67E6F2B9F4B068074preparation-assessments-v3.8.json
      /245/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-DAA646AA431D940D58029669preparation-assessments-v3.8.json
      /245/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-4F12B2E39129DD8236CC551Apreparation-assessments-v3.8.json
      /245/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-96A2742D96D8C3D89699F9E8preparation-assessments-v3.8.json
      /245/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-AACE6F8B0984DBE3CD2838EBpreparation-assessments-v3.8.json
      /245/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-858A03172D9DEC2637978ED2preparation-assessments-v3.8.json
      /245/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-843DB41D433F91F969258CC9preparation-assessments-v3.8.json
      /245/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-1118F3785EB598FDCE0ED58Apreparation-assessments-v3.8.json
      /245/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-2E01F57CA44BEA2157F3FB65preparation-assessments-v3.8.json
      /245/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-4B200B47ACED58C77DD0CE53preparation-assessments-v3.8.json
      /245/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-168FF81F3F96CE1586C4A45Epreparation-assessments-v3.8.json
      /245/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-6A5D01DEAF88DC5F0B5B0E26preparation-assessments-v3.8.json
      /245/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-08B27B1C844ABE3E8D6C594Fpreparation-assessments-v3.8.json
      /245/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-254277CC8FEB9705EDB7B5A6preparation-assessments-v3.8.json
      /245/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-E83001BE517046AF34FAFF5Apreparation-assessments-v3.8.json
      /245/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-27D154503A5F0B97B87E7BCFpreparation-assessments-v3.8.json
      /245/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-776CEAC441492113C76C485Fpreparation-assessments-v3.8.json
      /245/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-533FF13D2C7D7721A58B0330preparation-assessments-v3.8.json
      /245/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-A46CF76D3587DE4FA0BFA51Fpreparation-assessments-v3.8.json
      /245/route_presence/structured_dilution      		Historical; current review incomplete
      H51-3DBF5C8B73DA290A07FE657Cpreparation-assessments-v3.8.json
      /245/route_presence/iv_push      		Historical; current review incomplete
      H51-2B7C87E494EDC515FC6275A4preparation-assessments-v3.8.json
      /245/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-1FF14AEDF091B82F96A9EAACpreparation-assessments-v3.8.json
      /245/route_presence/pediatric_source      		Historical; current review incomplete
      H51-55E65C86FDD21C662D9EBA05preparation-assessments-v3.8.json
      /245/route_presence/neonatal_source      		Historical; current review incomplete
      H51-60A380301544E90385909CF9preparation-assessments-v3.8.json
      /245/legacy_reference/status      		Historical; current review incomplete
      H51-3F5480B3E3EF56AB37D45EB8preparation-assessments-v3.8.json
      /245/label_resolution/status      		Historical; current review incomplete
      H51-1A79743810A0262D58DE4EC2preparation-assessments-v3.8.json
      /245/source_files/0      		Historical; current review incomplete
      H51-B23B4904668011E95E811FE3preparation-assessments-v3.8.json
      /245/source_files/1      		Historical; current review incomplete
      H51-A4E357960B9FA0FFDFDA9855preparation-assessments-v3.8.json
      /245/source_files/2      		Historical; current review incomplete
      H51-1A4215D78D10BFF9D65F9CD6preparation-assessments-v3.8.json
      /245/source_files/3      		Historical; current review incomplete
      H51-6F441167E48ABAD217FF1BF8preparation-assessments-v3.8.json
      /245/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top